Inositol vs Metformin for PCOS: What the Evidence Actually Says

The evidence in one paragraph

Across the largest head-to-head trials and the 2018 Cochrane review, myo-inositol (4,000 mg/day, often paired with 100 mg D-chiro-inositol in a 40:1 ratio) produces insulin-sensitivity, ovulation, and androgen improvements that are clinically comparable to metformin (1,500-2,000 mg/day) in women with PCOS, with substantially fewer gastrointestinal side effects. Metformin retains a stronger evidence base for severe insulin resistance, type 2 diabetes prevention, and pregnancy outcomes when started before conception. Combination therapy is studied and may produce additive benefits but should be initiated under physician supervision. The choice between them is a clinical decision that belongs with your doctor and depends on your phenotype, lab results, tolerability, and goals.

How metformin works

Mechanism of action

Metformin is a biguanide. Its primary mechanism is activation of AMP-activated protein kinase (AMPK), an energy-sensing enzyme inside cells. AMPK activation reduces hepatic gluconeogenesis (the liver makes less glucose), improves peripheral glucose uptake in muscle and fat tissue, and modestly reduces intestinal glucose absorption. The net effect is lower fasting insulin, lower fasting glucose, and improved insulin sensitivity, which downstream reduces ovarian androgen production in many women with PCOS.

Typical dosing for PCOS

Standard PCOS doses range from 1,500 to 2,000 mg/day, taken with food in divided doses (most commonly 500 mg with each meal, titrated up over 2-4 weeks to reduce GI side effects). Extended-release formulations (Glucophage XR) are often better tolerated. Lower doses (500-1,000 mg/day) are sometimes used for lean PCOS phenotypes or for women who are highly sensitive.

Common side effects and tolerability

Gastrointestinal side effects are the dominant tolerability issue. Approximately 20 to 30 percent of women experience nausea, diarrhea, abdominal cramping, or loss of appetite, particularly in the first 2 to 4 weeks. Most resolve with slow titration and taking the medication with food. Less common but important: vitamin B12 deficiency develops in roughly 6 to 30 percent of long-term users, and B12 status should be checked annually. Lactic acidosis is rare but serious and is the reason metformin is contraindicated in advanced kidney disease.

How myo-inositol works

Mechanism of action

Inositol is a vitamin-like nutrient that the body uses as a second messenger in insulin signaling. The two PCOS-relevant isomers are myo-inositol (MI) and D-chiro-inositol (DCI). MI is the predominant form in healthy ovarian tissue and is involved in follicle-stimulating hormone signaling and oocyte maturation. DCI is the form involved in muscle-tissue insulin signaling and androgen synthesis. In women with PCOS, the conversion of MI to DCI in the ovary is dysregulated, contributing to ovarian insulin resistance and excess androgen production. Supplementing with MI restores the physiologic 40:1 MI to DCI ratio in serum and corrects insulin signaling at the cellular level.

Myo-inositol vs D-chiro-inositol: why the 40:1 ratio matters

Healthy serum MI:DCI ratios are approximately 40:1. Higher DCI doses (used in some early trials) initially appeared promising but later trials showed worsening of egg quality at high DCI exposure, an effect now called the "DCI paradox." Current best-evidence formulations contain 4,000 mg of myo-inositol with 100 mg of D-chiro-inositol per day to mirror the physiologic ratio. Pure-MI formulations (no DCI) are also widely used and effective for most women.

Typical dosing for PCOS

The most-studied dose is 2,000 mg of myo-inositol twice daily for a total of 4,000 mg/day, often combined with 100 mg of D-chiro-inositol. Most clinical effects appear over 8 to 12 weeks. Some protocols add 200 mcg of folic acid to the formulation, particularly when conception is the goal.

Side effects and tolerability

Inositol is generally very well tolerated. Side effects are uncommon and are limited to mild GI symptoms (nausea, soft stools) at doses above 12 g/day, far above the standard PCOS dose. There are no known clinically significant drug interactions. Inositol is not contraindicated in pregnancy and has a long safety record across pregnancy trials.

Head-to-head: what the RCTs show

Insulin sensitivity and HOMA-IR

Multiple randomized controlled trials have directly compared myo-inositol to metformin on insulin-resistance markers. A 2017 randomized crossover trial in obese PCOS patients (Tagliaferri et al., Clinical Endocrinology) found that 6 months of myo-inositol (4,000 mg/day) and 6 months of metformin (1,500 mg/day) produced statistically equivalent reductions in HOMA-IR and fasting insulin. A 2008 trial by Genazzani and colleagues demonstrated that myo-inositol 2,000 mg/day for 12 weeks significantly reduced fasting insulin and HOMA-IR in overweight PCOS women. The 2018 Cochrane systematic review on inositol for subfertile women with PCOS concluded that inositol "may improve" insulin sensitivity and hormonal parameters, with the caveat that evidence quality is moderate and head-to-head comparisons are limited.

Ovulation rate and pregnancy outcomes

Trials report comparable improvements in ovulation rate between the two. Costantino et al. (2009) found that myo-inositol 4,000 mg/day for 16 weeks restored spontaneous ovulation in 72 percent of treated women with oligomenorrhea or amenorrhea, comparable to historical metformin response rates. For pregnancy outcomes specifically, metformin retains a slightly larger evidence base when started preconception, particularly in obese PCOS phenotypes, and is the option more commonly used in fertility clinics. Inositol is the preferred first-line option when GI tolerance is a concern or when the patient prefers to avoid pharmaceutical intervention.

Androgen levels (testosterone, free androgen index)

Both produce reductions in total testosterone and the free androgen index (FAI) over 12 to 24 weeks of treatment, with myo-inositol showing slightly more consistent reductions in FAI in head-to-head trials. The Costantino trial reported a statistically significant reduction in testosterone (from 96.6 to 43.3 ng/dL on average) over 14 weeks of myo-inositol treatment.

Weight, BMI, and waist circumference

Metformin is associated with modest weight reduction in PCOS (average 2-3 percent of body weight over 6-12 months), particularly in obese phenotypes. Myo-inositol shows smaller and less consistent effects on weight. Neither should be considered a primary weight-loss treatment, and both work best when combined with sustained dietary change and resistance exercise.

Side effects and tolerability

This is the largest practical difference between the two. Myo-inositol is well-tolerated by approximately 95 percent of users. Metformin produces meaningful GI side effects in 20 to 30 percent of users, with roughly 5 percent discontinuing treatment due to intolerance. For the patient who prioritizes tolerability and predictable adherence, myo-inositol has a clear advantage.

Comparison summary

When inositol is a reasonable first-line choice

• You have mild to moderate insulin resistance (HOMA-IR under approximately 4) without type 2 diabetes.
• You have GI sensitivity or have previously tried and discontinued metformin due to GI side effects.
• You prefer to start with an over-the-counter supplement before considering a prescription.
• You are trying to conceive and want a treatment with a long pregnancy safety record.
• Your primary symptoms are ovulatory dysfunction and androgen excess rather than overt hyperglycemia.

When metformin is the better choice

• You have type 2 diabetes, prediabetes, or HbA1c above 5.7 percent.
• You have severe insulin resistance (HOMA-IR above approximately 4-5) or fasting insulin above 20 mIU/L.
• You are obese with central adiposity and significant cardiometabolic risk markers.
• You need a treatment with prescription-grade quality control and insurance coverage.
• Your endocrinologist or reproductive endocrinologist specifically recommends it for fertility preparation in obese PCOS.

Combination therapy: the case for both

Several trials have studied combination myo-inositol plus metformin and reported additive benefits on insulin sensitivity and ovulation rate, particularly in women who responded incompletely to either monotherapy. The combination has been used safely in clinical practice, but should be initiated under physician supervision because of potential additive blood-sugar lowering. The most common practical pattern is metformin titrated to tolerance plus 4,000 mg/day myo-inositol added after 8 to 12 weeks of metformin alone if response has been incomplete.

How to talk to your doctor about this comparison

The most useful conversation with an endocrinologist or OB-GYN is grounded in your own labs and goals. Bring:

1. Your most recent labs: fasting glucose, fasting insulin (calculate HOMA-IR = glucose mg/dL × insulin mIU/L / 405), HbA1c, total testosterone, free androgen index, SHBG, and a lipid panel.
2. Your symptom and cycle history: regularity, length, hirsutism, acne, hair loss patterns.
3. Your goal: symptom management, fertility, weight loss, or general metabolic health (these often pull in different treatment directions).
4. Tolerability priorities: If GI side effects are a deal-breaker for you, say so. If cost or insurance coverage matters, say so. These are legitimate inputs to the decision.

The current best-evidence position from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS is that both metformin and inositol are reasonable options, that selection should be individualized, and that lifestyle interventions (diet and exercise) remain first-line for all PCOS phenotypes regardless of medication choice.

How PCOS Meal Planner supports your supplement and medication response

Inositol and metformin both work better when paired with a meal pattern that does not spike insulin in the first place. PCOS Meal Planner builds personalized weekly meal plans designed around insulin-sensitive macro targets (typically 30 to 40 percent carbs, 25 to 30 percent protein, 30 to 40 percent fat) and tracks symptom and meal patterns over time, so you can see whether a supplement or medication is moving the needle in combination with your diet.

Start a 7-day trial of PCOS Meal Planner

Frequently Asked Questions

Is inositol as effective as metformin for PCOS?

In multiple head-to-head randomized controlled trials, myo-inositol shows comparable improvements in insulin sensitivity, ovulation rate, and androgen levels to metformin in women with PCOS, with substantially fewer GI side effects. The evidence is strongest for the 4,000 mg/day myo-inositol dose, often combined with 100 mg D-chiro-inositol. Metformin retains a slightly stronger evidence base for severe insulin resistance, type 2 diabetes prevention, and obese fertility preparation.

Can you take inositol and metformin together?

Yes. Combination therapy has been studied in PCOS and may produce additive benefits on insulin sensitivity and ovulation, but should be initiated under physician supervision because of potential additive blood-sugar lowering. The common pattern is metformin titrated to tolerance plus myo-inositol 4,000 mg/day added if response to metformin alone has been incomplete after 8 to 12 weeks.

What is the right dose of myo-inositol for PCOS?

Most clinical trials use 4,000 mg of myo-inositol per day, typically split as 2,000 mg twice daily, often combined with 100 mg of D-chiro-inositol (the 40:1 ratio that mirrors physiological serum levels). Effects on insulin sensitivity typically appear by week 8, ovulation by week 12, and androgen reduction over 12 to 16 weeks.

Does metformin help with weight loss for PCOS?

Modestly. Metformin is associated with average reductions of 2 to 3 percent of body weight and small reductions in waist circumference over 6 to 12 months in PCOS. The bigger benefits are improvements in insulin sensitivity, cycle regularity, and (for women trying to conceive) ovulation rate. Metformin is not a weight-loss drug and should not be prescribed primarily for that purpose.

How long does inositol take to work for PCOS?

Most studies show measurable improvements in insulin sensitivity and HOMA-IR by 6 to 8 weeks, ovulation restoration within 8 to 12 weeks, and reductions in testosterone and free androgen index over 12 to 16 weeks. Cycle regularity often takes 3 to 4 cycles to fully stabilize. If there is no measurable change after 16 weeks at 4,000 mg/day, it is worth re-checking with your doctor.

Which has more side effects, metformin or inositol?

Metformin has substantially more side effects. Approximately 20 to 30 percent of women on metformin experience GI side effects (nausea, diarrhea, abdominal cramping), particularly in the first 2 to 4 weeks. Inositol at standard PCOS doses (4,000 mg/day) is well tolerated by approximately 95 percent of users, with side effects limited to mild GI symptoms at much higher doses.

Is inositol safe during pregnancy for PCOS women?

Myo-inositol has a long safety record across pregnancy trials and is sometimes continued during pregnancy under physician guidance, particularly for women at risk of gestational diabetes. The decision to continue or stop any supplement during pregnancy should always be made with your obstetric provider.

Sources

1. Tagliaferri V, Romualdi D, Immediata V, et al. Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clinical Endocrinology. 2017;86(5):725-730. PubMed: 28199020
2. Showell MG, Mackenzie-Proctor R, Jordan V, Hodgson R, Brown J. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2018;12(12):CD012378. PubMed: 30570133
3. Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. European Review for Medical and Pharmacological Sciences. 2009;13(2):105-110. PubMed: 19499845
4. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecological Endocrinology. 2008;24(3):139-144. PubMed: 18335328
5. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecological Endocrinology. 2012;28(7):509-515. PubMed: 22296306
6. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. European Review for Medical and Pharmacological Sciences. 2012;16(5):575-581. PubMed: 22774396
7. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023;120(4):767-793. PubMed: 37580056
8. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2012;(5):CD003053. PubMed: 22592687
9. National Institutes of Health, Office of Dietary Supplements. Inositol. NIH ODS
10. American College of Obstetricians and Gynecologists. Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics & Gynecology. 2018;131(6):e157-e171. PubMed: 29794677

Related reading on PCOS Meal Planner

• Semaglutide and PCOS: A New Frontier in Treatment
• Zinc for PCOS: Essential Mineral for Androgen Balance
• Why Am I Not Losing Weight on 1200 Calories with PCOS?
• PCOS Breakfast Ideas: 15 Quick, Hormone-Friendly Recipes
• Our Editorial Standards

How this article was researched

This article was researched from primary peer-reviewed studies in PubMed-indexed journals (Clinical Endocrinology, Gynecological Endocrinology, European Review for Medical and Pharmacological Sciences, Cochrane Database of Systematic Reviews, and Fertility and Sterility), the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, the ACOG 2018 Practice Bulletin on PCOS, and the NIH Office of Dietary Supplements. Every claim that is not common clinical knowledge is linked to a specific source in the Sources section above. This article is being prioritized for medical review by our contracted Registered Dietitian Nutritionist as part of our retroactive review program. See our editorial standards.